Recurrent Urinary Tract Infections in Women: Diagnosis and Management

Am Fam Physician. 2010 Sep 15;82(6):638-643.

  Patient information: See related handout on urinary tract infections in women.

  Related letter: "Ultrasensitive Culture in Urinary Tract Infection Diagnosis"

Recurrent urinary tract infections, presenting as dysuria or irritative voiding symptoms, are most commonly caused by reinfection with the original bacterial isolate in young, otherwise healthy women with no anatomic or functional abnormalities of the urinary tract. Frequency of sexual intercourse is the strongest predictor of recurrent urinary tract infections in patients presenting with recurrent dysuria. In those who have comorbid conditions or other predisposing factors, recurrent complicated urinary tract infections represent a risk for ascending infection or urosepsis. Escherichia coli is the most common organism in all patient groups, but Klebsiella, Pseudomonas, Proteus, and other organisms are more common in patients with certain risk factors for complicated urinary tract infections. A positive urine culture with greater than 102 colony-forming units per mL is the standard for diagnosing urinary tract infections in symptomatic patients, although culture is often unnecessary for diagnosing typical symptomatic infection. Women with recurrent symptomatic urinary tract infections can be treated with continuous or postcoital prophylactic antibiotics; other treatment options include self-started antibiotics, cranberry products, and behavioral modification. Patients at risk of complicated urinary tract infections are best managed with broad-spectrum antibiotics initially, urine culture to guide subsequent therapy, and renal imaging studies if structural abnormalities are suspected.

Recurrent urinary tract infections (UTIs) are common in women and associated with considerable morbidity and health care use. The clinical features, diagnostic testing, and causative organisms are often similar to those of single cases of UTI, although there are additional treatment strategies and prevention measures to consider with recurrent UTIs.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

A urine culture with greater than 102 colony-forming units per mL is considered positive in patients who have symptoms of UTI.

C

16

Continuous and postcoital antimicrobial prophylaxis have demonstrated effectiveness in reducing the risk of recurrent UTIs.

A

19

Cranberry products may reduce the incidence of recurrent symptomatic UTIs.

B

23, 25

Use of topical estrogen may reduce the incidence of recurrent UTIs in postmenopausal women.

B

26, 27

Treatment of complicated UTIs should begin with broad-spectrum antibiotic coverage, with adjustment of antimicrobial coverage guided by culture results.

C

11

Prophylactic antimicrobial therapy to prevent recurrent UTIs is not recommended for patients with complicated UTIs.

C

6


UTI = urinary tract infection.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limitedquality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

A urine culture with greater than 102 colony-forming units per mL is considered positive in patients who have symptoms of UTI.

C

16

Continuous and postcoital antimicrobial prophylaxis have demonstrated effectiveness in reducing the risk of recurrent UTIs.

A

19

Cranberry products may reduce the incidence of recurrent symptomatic UTIs.

B

23, 25

Use of topical estrogen may reduce the incidence of recurrent UTIs in postmenopausal women.

B

26, 27

Treatment of complicated UTIs should begin with broad-spectrum antibiotic coverage, with adjustment of antimicrobial coverage guided by culture results.

C

11

Prophylactic antimicrobial therapy to prevent recurrent UTIs is not recommended for patients with complicated UTIs.

C

6


UTI = urinary tract infection.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limitedquality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

Definitions and Epidemiology

Recurrent UTIs are symptomatic UTIs that follow resolution of an earlier episode, usually after appropriate treatment.1 Recurrent UTIs include relapses (i.e., symptomatic recurrent UTIs with the same organism following adequate therapy) and reinfection (i.e., recurrent UTIs with previously isolated bacteria after treatment and with a negative intervening urine culture, or a recurrent UTI caused by a second bacterial isolate).2 Most recurrent UTIs are thought to represent reinfection with the same organism.1 Recurrent UTIs are common among otherwise healthy young women with anatomically and physiologically normal urinary tracts.2 One study showed that of college women with a first UTI, 27 percent had at least one cultureconfirmed recurrence within the following six months, and 2.7 percent experienced a second recurrence over the same period.3 In a primary care setting, 53 percent of women older than 55 years and 36 percent of younger women had a recurrence within one year.4

In symptomatic women, predictors of recurrent UTIs include symptoms following intercourse, signs or symptoms of pyelonephritis, and prompt resolution of symptoms with antibiotics. Nocturia and persistence of symptoms between UTI episodes are strong negative predictors for recurrent infection.5

Another group of patients who present with recurrent UTIs are those who have predisposing medical conditions placing them at increased risk of developing complicated UTIs, with attendant risks of ascending infection (pyelonephritis) or urosepsis. The definition of complicated UTI is imprecise, but the term usually is applied to patients with a predisposing structural or functional abnormality of the genitourinary tract.6 Ascending infection, antibiotic resistance, and the need for prolonged therapy are often involved.

Causative Factors and Pathogenesis

Escherichia coli is the predominant uropathogen (80 percent) isolated in acute community-acquired uncomplicated UTIs, followed by Staphylococcus saprophyticus (10 to 15 percent). Enterococcus, Klebsiella, Enterobacter, and Proteus species are less common causes.7

In recurrent uncomplicated UTIs, reinfection occurs when the initially infecting bacteria persist in the fecal flora after elimination from the urinary tract, subsequently recolonizing the introitus and bladder.1 A number of host factors appear to predispose otherwise healthy young women to recurrent UTIs. These include local pH and cervicovaginal antibody changes in the vagina; greater adherence of uropathogenic bacteria to the uroepithelium; and possibly pelvic anatomic differences, such as shorter urethra-to-anus distance.

Diabetes mellitus, neurologic conditions, chronic institutional residence, and chronic indwelling urinary catheterization are important predisposing factors for complicated UTIs. In affected patients, organisms that are typically less virulent may cause marked illness, although E. coli infection remains the most common organism in nearly all patient groups. Klebsiella and group B streptococcus infections are relatively more common in patients with diabetes, and Pseudomonas infections are relatively more common in patients with chronic catheterization. Proteus mirabilis i s a c ommon u ropathogen i n p atients with indwelling catheters, spinal cord injuries, or structural abnormalities of the urinary tract.7

Risk Factors

The strongest risk factor for recurrent UTIs in young women is frequency of sexual intercourse. This and other risk factors are listed in Table 1.8 There is no proven association between recurrent UTIs and pre- or postcoital voiding patterns, frequency of urination, wiping patterns, douching, use of tight undergarments, or delayed voiding habits.1,8 A case-control study of postmenopausal women found that mechanical and physiologic factors affecting bladder emptying (incontinence, cystocele, and postvoiding residual urine) were strongly associated with recurrent UTIs.9 An increased postvoid residual urinary volume (i.e., more than about 50 mL) is an independent risk factor for recurrent UTIs in postmenopausal women.10

Table 1.

Risk Factors for Recurrent UTIs

Risk factor Odds ratio (95% confidence interval)

Intercourse in the past month

> 9 times

10.3 (5.8 to 18.3)

4 to 8 times

5.8 (3.1 to 10.6)

Age at first UTI ≥ 15 years

3.9 (1.9 to 8.0)

Maternal history of UTIs

2.3 (1.5 to 3.7)

New sex partner in the past year

1.9 (1.2 to 3.2)

Spermicide use in the past year

1.8 (1.1 to 2.9)


UTI = urinary tract infection.

Adapted with permission from Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. J Infect Dis. 2000;182(4):1181.

Table 1.   Risk Factors for Recurrent UTIs

View Table

Table 1.

Risk Factors for Recurrent UTIs

Risk factor Odds ratio (95% confidence interval)

Intercourse in the past month

> 9 times

10.3 (5.8 to 18.3)

4 to 8 times

5.8 (3.1 to 10.6)

Age at first UTI ≥ 15 years

3.9 (1.9 to 8.0)

Maternal history of UTIs

2.3 (1.5 to 3.7)

New sex partner in the past year

1.9 (1.2 to 3.2)

Spermicide use in the past year

1.8 (1.1 to 2.9)


UTI = urinary tract infection.

Adapted with permission from Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. J Infect Dis. 2000;182(4):1181.

A variety of factors place patients at risk of complicated UTIs (Table 2),6,11 and recurrent infection is common.

Table 2.

Predisposing Factors for Complicated Urinary Tract Infection

Immunosuppression

Chronic renal insufficiency

Diabetes mellitus

Immunosuppressant medications

Renal transplant

Nosocomial factors and instrumentation

Exposure to antibiotic-resistant bacteria

Indwelling urinary catheter

Intermittent catheterization

Nephrostomy tube

Ureteral stent

Urinary tract anatomic abnormality

Polycystic kidney disease

Urethral valves

Vesicoureteral reflux

Urinary tract obstruction

Bladder outlet obstruction

Congenital abnormality

Ureteral or urethral stricture

Urolithiasis

Voiding dysfunction

Cystocele

Multiple sclerosis

Neurogenic bladder


Information from references 6 and 11.

Table 2.   Predisposing Factors for Complicated Urinary Tract Infection

View Table

Table 2.

Predisposing Factors for Complicated Urinary Tract Infection

Immunosuppression

Chronic renal insufficiency

Diabetes mellitus

Immunosuppressant medications

Renal transplant

Nosocomial factors and instrumentation

Exposure to antibiotic-resistant bacteria

Indwelling urinary catheter

Intermittent catheterization

Nephrostomy tube

Ureteral stent

Urinary tract anatomic abnormality

Polycystic kidney disease

Urethral valves

Vesicoureteral reflux

Urinary tract obstruction

Bladder outlet obstruction

Congenital abnormality

Ureteral or urethral stricture

Urolithiasis

Voiding dysfunction

Cystocele

Multiple sclerosis

Neurogenic bladder


Information from references 6 and 11.

Diagnosis

Common differential diagnoses for recurrent dysuria are listed in Table 3.12

Table 3.

Differential Diagnosis of Recurrent Dysuria

Diagnosis Associated features

Acute pyelonephritis

Nausea, fever, flank pain, costovertebral angle tenderness, pyuria with casts

Atrophic vaginitis

Postmenopausal women, no infectious etiology

Bladder cancer

Frequency, urgency, hematuria

Cystitis

Frequency, urgency, pyuria, bacteriuria, urinary dipstick positive for nitrates

Genital herpes

Dysuria, fever, vulvar pain, grouped vesicles, tender inguinal adenopathy

Interstitial cystitis

Frequency, urgency, long-standing symptoms, pain in bladder or urethra relieved by urination; negative urine cultures; ulcers or glomerulations (bladder hemorrhages) identified on cystoscopy

Irritant cystitis

Symptoms related to dietary intake, chemical irritant, or other exposures

Overactive bladder

Urgency, frequency, and possibly incontinence,

without dysuria

Sexually transmitted infection

Vaginal discharge, history of unprotected sexual intercourse

Urethritis

Delayed symptoms or asymptomatic, history of unprotected sexual intercourse, positive test for Neisseria gonorrhoeae or Chlamydia trachomatis

Vaginitis

External irritation, dyspareunia, vaginal discharge, positive potassium hydroxide or wet-mount preparation


Information from reference 12.

Table 3.   Differential Diagnosis of Recurrent Dysuria

View Table

Table 3.

Differential Diagnosis of Recurrent Dysuria

Diagnosis Associated features

Acute pyelonephritis

Nausea, fever, flank pain, costovertebral angle tenderness, pyuria with casts

Atrophic vaginitis

Postmenopausal women, no infectious etiology

Bladder cancer

Frequency, urgency, hematuria

Cystitis

Frequency, urgency, pyuria, bacteriuria, urinary dipstick positive for nitrates

Genital herpes

Dysuria, fever, vulvar pain, grouped vesicles, tender inguinal adenopathy

Interstitial cystitis

Frequency, urgency, long-standing symptoms, pain in bladder or urethra relieved by urination; negative urine cultures; ulcers or glomerulations (bladder hemorrhages) identified on cystoscopy

Irritant cystitis

Symptoms related to dietary intake, chemical irritant, or other exposures

Overactive bladder

Urgency, frequency, and possibly incontinence,

without dysuria

Sexually transmitted infection

Vaginal discharge, history of unprotected sexual intercourse

Urethritis

Delayed symptoms or asymptomatic, history of unprotected sexual intercourse, positive test for Neisseria gonorrhoeae or Chlamydia trachomatis

Vaginitis

External irritation, dyspareunia, vaginal discharge, positive potassium hydroxide or wet-mount preparation


Information from reference 12.

Key steps in the diagnostic evaluation for recurrent UTIs include confirming the presence of a bacterial UTI, assessing the patient for risk factors and predisposing factors for complicated infection, and identifying a potentially causative organism. Figure 1 provides an algorithm for the assessment of women presenting with one or more UTI symptoms.13

Figure 1.

Algorithmic approach to the assessment of women with symptoms of urinary tract infection (UTI).

Adapted with permission from Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? JAMA . 2002;287(20):2707.

View Large


Figure 1.

Algorithmic approach to the assessment of women with symptoms of urinary tract infection (UTI).

Adapted with permission from Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? JAMA . 2002;287(20):2707.


Figure 1.

Algorithmic approach to the assessment of women with symptoms of urinary tract infection (UTI).

Adapted with permission from Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? JAMA . 2002;287(20):2707.

Women with one symptom of UTI have an infection probability of about 50 percent.13 In one systematic review, a combination of symptoms (i.e., dysuria, frequency, and absence of vaginal irritation or discharge) raised the probability of UTI to more than 90 percent,13 suggesting that history alone is often sufficient to confirm diagnosis. A decision aid to reduce unnecessary antibiotic use for acute cystitis revealed three variables (i.e., dysuria, presence of greater than trace leukocytes, and any positive nitrites) that were most strongly associated with a positive urine culture. 14 However, history, physical examination, or urine dipstick analysis alone is not sufficient to reliably rule out UTI.

The typical standard for diagnosing UTI is “significant” bacteria in a clean-catch or catheterized urine specimen.13 Historically this has been defined as at least 105 colony-forming units per mL, but in symptomatic women a uropathogen concentration of greater than 102 colony-forming units per mL may have the best combination of sensitivity and specificity, and should be used for diagnosis when culture is required.13,15,16 Although UTIs are often treated empirically in the office setting, with a urine culture obtained when the diagnosis is unclear or the symptoms continue despite antibiotic treatment, culture may be necessary in patients with recurrent UTIs to confirm the diagnosis and guide antibiotic therapy.

It is particularly important to review risk factors for complicated UTIs in women with UTI who do not respond to antibiotics, or for those with recurrent UTIs and no evident predisposing factors. In patients with neurologic illnesses (e.g., spinal cord injury) or indwelling urinary catheters, a high index of suspicion for UTI is necessary in nonspecific presentations.6

There are no specific guidelines or indications for imaging studies in women who have recurrent UTIs but no known underlying medical or anatomic conditions. Reasonable indications for ultrasonography or computed tomography (CT) include recurrent noncoital UTIs, persistent hematuria associated with UTIs, acute pyelonephritis, or evidence of renal insufficiency.11

Recurrent UTIs are common among women with dysfunctional voiding, defined as increased external sphincter activity during voluntary voiding in otherwise neurologically healthy patients; this may present as urinary frequency, urgency, hesitancy, or incomplete bladder emptying. There are no guidelines for urodynamic evaluation in such patients.

Diagnostic evaluation in the setting of predisposing factors (i.e., complicated UTI) differs in that a urine culture including antibiotic sensitivities is almost always required to guide therapy. Obtaining a serum chemistry panel and assessing the patient's general medical status (e.g., hydration, toxicity) are important. For older or immunocompromised patients and those who have congenital malformations of the kidney, CT or ultrasonography is usually required.11

Treatment

Treatment of an initial recurrence of UTI is the same as for other cases of uncomplicated cystitis. The antimicrobial susceptibility profile for uropathogens in a community should guide treatment decisions. A threeday course of trimethoprim/sulfamethoxazole (TMPSMX; Bactrim, Septra) is the current standard therapy, with three days of trimethoprim or a fluoroquinolone (i.e., ofloxacin, norfloxacin [Noroxin], or ciprofloxacin [Cipro]) being equally effective. 17 Because fluoroquinolones are commonly used to treat complicated UTIs and other nonurinary disorders, resistance to this drug class is a concern. Consequently, fluoroquinolones are not recommended as initial empiric therapy except in communities with high rates of resistance to other agents.17 With increasing concern for E. coli resistance to TMP-SMX (up to 15 to 20 percent in some areas of the United States), nitrofurantoin (Macrodantin) is a safe and generally effective agent if administered for seven days.1

As the number and frequency of recurrences increase, the treatment strategy is less well-defined. Fluoroquinolones and nitrofurantoin become better options as suspicion for TMP-SMX resistance increases.18

In cases of recurrence, a test-of-cure urine culture performed approximately one to two weeks after completion of antibiotic therapy may be considered to confirm clearance.2

Patients with recurrent UTIs should be counseled about risk factors such as spermicide use, frequent sexual intercourse, and new sex partners, as well as about preventive measures.

Prevention

ANTIBIOTIC PROPHYLAXIS

Antimicrobial prophylaxis has proved effective in reducing the risk of recurrent UTIs in women with two episodes of infection in the previous year. Continuous prophylaxis for six to 12 months reduces the rate of UTIs during the prophylaxis period, with no difference between the six-month and 12-month treatment groups after cessation of prophylaxis. 19  Prophylactic antibiotic selection should be made on the basis of community resistance patterns, side effects, and local costs. Various dosages of prophylactic antibiotics have been suggested (Table 4),1,6,19,20 but no conclusive evidence supports selection of a particular drug, dosage, or duration or schedule of treatment.

Table 4.

Continuous vs. Postcoital Antimicrobial Prophylaxis for Recurrent Urinary Tract Infections

Antimicrobial agent Continuous prophylaxis (daily dosage)* Cost (brand) Postcoital prophylaxis (one-time dose) In retail discount programs§

Cephalexin (Keflex)

125 to 250 mg

$14 ($66); only available in 250-mg capsule

250 mg

Ciprofloxacin (Cipro)

125 mg

$12 ($68); half tablet (250 mg) for 30 days

125 mg

Nitrofurantoin (Macrodantin)

50 to 100 mg

$28 ($68) for 50-mg dose

50 to 100 mg

Norfloxacin (Noroxin)

200 mg

NA ($63); half tablet (400 mg) for 30 days

200 mg

Trimethoprim (Proloprim)

100 mg

$20 (NA)

100 mg

Trimethoprim/sulfamethoxazole (Bactrim, Septra)

40/200 mg

$16 ($26); half tablet for 30 days

40/200 to 80/400 mg


NA = not applicable.

*—Typically taken at night.1

†—Estimated retail price of one month's treatment based on information obtained at http://www.drugstore.com (accessed July 28, 2010).

‡—Taken within two hours of intercourse.1,20

§—May be available at discounted prices ($10 or less for one month's treatment) at one or more national retail chains.

Information from references 1, 6, 19, and 20.

Table 4.   Continuous vs. Postcoital Antimicrobial Prophylaxis for Recurrent Urinary Tract Infections

View Table

Table 4.

Continuous vs. Postcoital Antimicrobial Prophylaxis for Recurrent Urinary Tract Infections

Antimicrobial agent Continuous prophylaxis (daily dosage)* Cost (brand) Postcoital prophylaxis (one-time dose) In retail discount programs§

Cephalexin (Keflex)

125 to 250 mg

$14 ($66); only available in 250-mg capsule

250 mg

Ciprofloxacin (Cipro)

125 mg

$12 ($68); half tablet (250 mg) for 30 days

125 mg

Nitrofurantoin (Macrodantin)

50 to 100 mg

$28 ($68) for 50-mg dose

50 to 100 mg

Norfloxacin (Noroxin)

200 mg

NA ($63); half tablet (400 mg) for 30 days

200 mg

Trimethoprim (Proloprim)

100 mg

$20 (NA)

100 mg

Trimethoprim/sulfamethoxazole (Bactrim, Septra)

40/200 mg

$16 ($26); half tablet for 30 days

40/200 to 80/400 mg


NA = not applicable.

*—Typically taken at night.1

†—Estimated retail price of one month's treatment based on information obtained at http://www.drugstore.com (accessed July 28, 2010).

‡—Taken within two hours of intercourse.1,20

§—May be available at discounted prices ($10 or less for one month's treatment) at one or more national retail chains.

Information from references 1, 6, 19, and 20.

The duration of prophylaxis should be guided by the severity of patient symptoms and by physician and patient preference. Six months of treatment, followed by observation for reinfection after discontinuing prophylaxis, has been empirically recommended.1 Some authorities have recommended longer courses (two to five years) in patients who continue to have recurrent symptomatic infections.

Postcoital prophylaxis may be preferable in women with UTIs temporally related to intercourse. No marked difference in recurrent UTIs has been noted when using postcoital prophylaxis compared with daily prophylaxis, 19 and depending on the frequency of sexual intercourse, postcoital prophylaxis usually results in less antibiotic use.6,19  Various postcoital antibiotic regimens are described in Table 4.1,6,19,20

Although not strictly a preventive strategy, self-initiated treatment is an option for some patients. Women with previous UTIs who are able to recognize the symptoms can be treated effectively with self-started antibiotic therapy.21,22 Women can be given a prescription for a three-day antibiotic regimen and instructed to start therapy when symptoms develop. If there is no improvement in 48 hours, the patient should be evaluated clinically. 2 This strategy should be restricted to women who have clearly documented recurrent UTIs and are motivated, adhere to medical instructions, and have a good relationship with a health care professional.1

OTHER PREVENTIVE MODALITIES

Behavioral changes can affect the frequency of UTI recurrence. Managing recurrent infections should include modification of known risk factors.

Cranberry products seem to notably reduce the recurrence of symptomatic cystitis. In one Cochrane review,23 cranberry juice showed moderate benefit in reducing the risk of UTI in women with a history of recurrent infection, based on two well-designed randomized trials. Although there is no clear evidence about dosage or duration of use,20 small studies have reported that a daily intake of 150 to 750 mL of cranberry juice or concentrated equivalent is effective in preventing recurrent UTIs.24,25

Patients also may be counseled about the theory and anecdotal evidence behind postcoital voiding, although no controlled studies support this intervention.

Several studies of postmenopausal women have demonstrated the effectiveness of using topical estrogen (0.5 mg of estriol vaginal cream nightly for two weeks, then twice weekly for eight months), but adverse effects are common.26,27

Recurrent Complicated UTIs

The principles of treating recurrent complicated UTIs include early use of broad-spectrum antibiotics, with adjustment of antibiotic coverage based on culture results,11 and attempts to relieve any existing urinary obstruction based on the results of imaging studies. Antibiotic regimens and treatment recommendations are not well-defined in this patient population; the wide variety of predisposing factors and causative organisms, and the variable antibiotic resistance patterns, make uniform recommendations difficult.6

Initiation of treatment depends on development of new symptoms (which may be subtle) in patients with chronic bacteriuria. Antibiotic selection should be based on community resistance patterns, and empiric initial treatment should be guided by likely organisms. The antibiotic regimen should be narrowed, when possible, to within 48 to 72 hours based on culture results. In general, patients who are hemodynamically stable and able to tolerate and absorb oral medications can be treated with oral agents such as fluoroquinolones. If parenteral therapy is needed, multiple agents (i.e., aminoglycosides, fluoroquinolones, ceftazidime [Fortaz], carbapenems, and piperacillin/tazobactam [Zosyn]) have been reported to achieve high rates of clinical cure. Duration of therapy should be determined on an individual basis but is typically 10 to 14 days. Selected guidelines for the management of recurrent complicated UTIs are listed in Table 5.6

Table 5.

Guidelines for the Management of Recurrent Complicated UT Is

A single urine specimen with a quantitative count of at least 105 colony-forming units per mL is consistent with a diagnosis of UTI in asymptomatic patients.

If clinically feasible, initiation of antimicrobial therapy should be delayed until urine culture results are available.

Parenteral antimicrobial therapy is indicated if patients are unable to tolerate oral therapy, have impaired gastrointestinal absorption, have hemodynamic instability, or if the infecting organism is known or suspected to be resistant to oral agents.

The duration of therapy should be seven days for patients with lower urinary tract symptoms, and 10 to 14 days for patients with upper urinary tract symptoms or sepsis syndrome.

Patients with chronic use of urologic devices should receive the shortest possible duration of therapy to limit antimicrobial pressure leading to resistance.

Whenever possible, genitourinary abnormalities should be corrected.

Prophylactic antimicrobial therapy to prevent recurrent UTIs is not recommended for patients with complicated UTIs.

Suppressive antimicrobial therapy is indicated to prevent frequent, recurrent infection for selected patients with persistent genitourinary abnormalities.

For young women with catheter-acquired UTIs, treatment of bacteriuria persisting 48 hours after catheter removal may beconsidered.


UTI = urinary tract infection.

Information from reference 6.

Table 5.   Guidelines for the Management of Recurrent Complicated UT Is

View Table

Table 5.

Guidelines for the Management of Recurrent Complicated UT Is

A single urine specimen with a quantitative count of at least 105 colony-forming units per mL is consistent with a diagnosis of UTI in asymptomatic patients.

If clinically feasible, initiation of antimicrobial therapy should be delayed until urine culture results are available.

Parenteral antimicrobial therapy is indicated if patients are unable to tolerate oral therapy, have impaired gastrointestinal absorption, have hemodynamic instability, or if the infecting organism is known or suspected to be resistant to oral agents.

The duration of therapy should be seven days for patients with lower urinary tract symptoms, and 10 to 14 days for patients with upper urinary tract symptoms or sepsis syndrome.

Patients with chronic use of urologic devices should receive the shortest possible duration of therapy to limit antimicrobial pressure leading to resistance.

Whenever possible, genitourinary abnormalities should be corrected.

Prophylactic antimicrobial therapy to prevent recurrent UTIs is not recommended for patients with complicated UTIs.

Suppressive antimicrobial therapy is indicated to prevent frequent, recurrent infection for selected patients with persistent genitourinary abnormalities.

For young women with catheter-acquired UTIs, treatment of bacteriuria persisting 48 hours after catheter removal may beconsidered.


UTI = urinary tract infection.

Information from reference 6.

REFERRAL

There are no clear guidelines for referral of patients with recurrent or complicated UTIs. Most patients with recurrent uncomplicated UTIs can be treated by family physicians. Patients with complicated UTIs may require consultation from subspecialists in urology, infectious disease, or renal medicine.

The Authors

CHARLES M. KODNER, MD, is an associate professor in the Department of Family and Geriatric Medicine at the University of Louisville (Kentucky) School of Medicine.

EMILY K. THOMAS GUPTON, DO, MPH, is a family physician at Primary Care Medical Center, Murray, Ky. At the time this article was written, Dr. Gupton was a resident in the Department of Family and Geriatric Medicine at the University of Louisville School of Medicine.

Address correspondence to Charles M. Kodner, MD, University of Louisville School of Medicine, Med Center One Building, Louisville, KY 40292. Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

REFERENCES

1. Hooton TM. Recurrent urinary tract infection in women Int J Antimicrob Agents. 2001;17(4):259–268.

2. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 91: Treatment of urinary tract infections in nonpregnant women. Obstet Gynecol. 2008;111(3):785–794.

3. Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health. 1990;80(3):331–333.

4. Ikäheimo R, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis. 1996;22(1):91–99.

5. Gopal M, et al. Clinical symptoms predictive of recurrent urinary tract infections. Am J Obstet Gynecol. 2007;197(1):74.e1–74.e4.

6. Nicolle L; AMMI Canada Guidelines Committee. Complicated urinary tract infection in adults Can J Infect Dis Med Microbiol. 2005;16(6):349–360.

7. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med. 2002;113(suppl 1A):14S–19S.

8. Scholes D, et al. Risk factors for recurrent urinary tract infection in young women. J Infect Dis. 2000;182(4):1177–1182.

9. Raz R, et al. Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis. 2000;30(1):152–156.

10. Stern JA, et al. Residual urine in an elderly female population: novel implications for oral estrogen replacement and impact on recurrent urinary tract infection. J Urol. 2004;171(2 pt 1):768–770.

11. Neal DE Jr. Complicated urinary tract infections. Urol Clin North Am. 2008;35(1):13–22.

12. Bogart LM, et al. Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women [published correction appears in J Urol. 2007;177(6):2402]. J Urol. 2007;177(2):450–456.

13. Bent S, et al. Does this woman have an acute uncomplicated urinary tract infection? JAMA. 2002;287(20):2701–2710.

14. McIsaac WJ, et al. Validation of a decision aid to assist physicians in reducing unnecessary antibiotic drug use for acute cystitis. Arch Intern Med. 2007;167(20):2201–2206.

15. Stamm WE, et al. Diagnosis of coliform infection in acutely dysuric women. N Engl J Med. 1982;307(8):463–468.

16. Hooton TM, et al. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am. 1997;11(3):551–581.

17. Warren JW, et al. Infectious Diseases Society of America (IDSA). Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis. 1999;29(4):745–758.

18. Drekonja DM, et al. Urinary tract infections. Prim Care. 2008;35(2):345–367.

19. Albert X, et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3): CD001209.

20. Sen A. Recurrent cystitis in non-pregnant women. Clin Evid. 2006;(15): 2558–2564.

21. Schaeffer AJ, et al. Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. J Urol. 1999;161(1):207–211.

22. Gupta K, et al. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med. 2001;135(1):9–16.

23. Jepson RG, et al. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2008;(1):CD001321.

24. Sheffield JS, et al. Urinary tract infection in women. Obstet Gynecol. 2005;106(5 pt 1):1085–1092.

25. Kontiokari T, et al. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ. 2001;322(7302):1571

26. Raz R, et al. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11):753–756.

27. Perrotta C, et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;(2):CD005131.


Copyright © 2010 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article